PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative ...
Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results